Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Adocia (ADOC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.36 0.00    0.00%
30/04 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 37,561
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 8.20 - 8.43
Type:  Equity
Market:  France
ISIN:  FR0011184241 
Adocia 8.36 0.00 0.00%

Adocia Company Profile

 
Read the Adocia company profile to learn more about the business and the management team. View Adocia facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

110

Equity Type

ORD

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Contact Information

Address 115 Avenue Lacassagne
Lyon, 69003
France
Phone 33 4 72 61 06 10
Fax 33 4 72 36 39 67

Top Executives

Name Age Since Title
Ekaterina Smirnyagina 56 2013 Independent Director
Jay S. Skyler 75 2016 Chairman of Diabetes Medical Advisory Board
Olivier Martinez 52 2011 Director
Stephane Boissel 54 2021 Independent Director
Gérard Soula 78 2005 Co-Founder & Chairman of the Board
Olivier Soula 53 2011 Co-Founder, CEO & Director
Denis Raccah - 2016 Member of the Diabetes Medical Advisory Board
Chantal Mathieu - 2016 Member of the Diabetes Medical Advisory Board
Steve Edelman - 2019 Member of Global Diabetes Medical Advisory Board
Vanita Aroda - 2016 Member of the Diabetes Medical Advisory Board
Bruce W. Bode - 2016 Member of the Diabetes Medical Advisory Board
Daniel Einhorn - 2016 Member of the Diabetes Medical Advisory Board
Carol Wysham - 2019 Member of Global Diabetes Medical Advisory Board
Alexander Zan Fleming - 2023 Member of the Diabetes Medical Advisory Board
Mads Dall - 2023 Independent Director
Tim Heise - 2023 Member of the Diabetes Medical Advisory Board
Thomas R. Pieber - 2023 Member of the Diabetes Medical Advisory Board
Matthew C. Riddle - 2023 Member of the Diabetes Medical Advisory Board
John B. Buse - 2016 Member of the Diabetes Medical Advisory Board
Vivian A. Fonseca - 2016 Member of the Diabetes Medical Advisory Board
Claudia Mitchell - 2021 Independent Director
Katherine S. Bowdish 66 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADOC Price Commentary

Write your thoughts about Adocia
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email